Using community health workers and mobile health to improve HIV treatment adherence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of a Community Health Worker (CHW) intervention combined with a mobile telehealth (M-Health) component in achieving long-term viral suppression in Black individuals with poorly controlled HIV. Participants will receive support and counseling from CHWs to enhance their treatment adherence. The study focuses on individuals aged 18 and older who are receiving care at the University of Miami/Jackson Memorial Health System and self-identify as Black. The intervention seeks to address barriers to care and improve health outcomes in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ages 18 years or older
* Miami-Dade Resident at time of enrollment
* self-identify as Black
* Viral load \> 200 mL within the last 6-months (VL must be verified via electronic medical record or lab report prior to enrollment)

Exclusion Criteria:

* Any other condition(s) that the treating clinician determines would limit participant from meaningful study participation.

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Sonjia Kenya, EdD — University of Miami
• Study coordinator: Ashley J Gray, MPH
• Email: ajg2940@miami.edu
• Phone: 3052431497

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intervention to improve PrEP use among Black men who have sex with men

  This study is testing a new support program to help Black men who have sex with men start and stick with PrEP to prevent HIV.

  Recruiting at 3 sites Brown University · Atlanta, Georgia and 2 other locations · NCT06872307

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• Optimizing HIV Therapy for AIDS-Related Lymphoma Patients

  This study tests whether long-acting HIV medicines given during lymphoma treatment work better at keeping the virus suppressed than standard oral therapy in adults with AIDS-related lymphoma.

  Recruiting Shanghai Public Health Clinical Center · Shanghai, Shanghai Municipality · NCT07727642

• Colchicine to see if it reduces coronary artery inflammation in people with HIV

  This study tests whether low-dose colchicine can lower inflammation in the coronary arteries of people with HIV who are at high heart-disease risk, compared with a placebo.

  Recruiting at 2 sites Phase 2 Instituto de Investigación Hospital Universitario La Paz · Barcelona and 3 other locations · NCT07704164

• Darunavir/ritonavir plus lamivudine vs darunavir/ritonavir plus tenofovir alafenamide/emtricitabine in virologically suppressed adults with HIV

  This trial tests whether a two-drug regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus TAF/FTC) in adults with HIV who have stable viral suppression.

  Recruiting Phase 4 Instituto Mexicano del Seguro Social · Mexico City, Mexico City · NCT07678268

• Dental care for people living with HIV in Pays de la Loire

  This study looks at whether people living with HIV in Pays de la Loire need any special dental management based on their health data.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07552038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.